Skip to main content
Premium Trial:

Request an Annual Quote

Nuclea, Aelan Ink Biomarker Test, Companion Dx Deal

NEW YORK (GenomeWeb) – Nuclea Biotechnologies announced today that it has partnered with Aelan Cell Technologies to develop, validate, and commercialize novel biomarker tests and companion diagnostics, with a focus on cancer, metabolic disorders, neurodegeneration, aging, and aging-related disorders.

Nuclea said that the arrangement would combine its expertise in proteomics with Aelan's genomics know-how. Specifically, Nuclea will provide protein analysis of the human stem cells used as models for the tests, while Aelan will provide DNA and mRNA analysis.

Aelan will also research the biological pathways associated with aging and life extension, Nuclea said, to identify which age-related biological processes are activated in various patient populations during interventions including supplements, drugs, and exercise. This, the company added, will enable the discovery of age-related biomarkers across diseases such as early-stage cancer and neurodegeneration.

Financial terms of the deal were not disclosed.

"Incorporating prognostic and predictive biomarkers into clinical trial strategies, in addition to therapeutic decision-making, is essential to disentangling the complexities of the pathogenic process, drug pharmacodynamics, and epidemiological heterogeneity," Aelan CEO Victoria Lunyak said in a statement. "Our goal is to develop tests based on biomarker panels identified in next-generation sequencing and mass spectrometry-based proteomics studies."

"This relationship provides access to novel biomarkers and data analysis platforms, as well as Aelan's expertise in stem cell biology and epigenetics," Nuclea President and CEO Patrick Muraca added in the statement. "Nuclea has complementary manufacturing and commercialization capabilities that facilitate the development of diagnostics with robust clinical utility."

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.